Harness Critical Regulatory Insights, Achieve Scalable AI Implementation Whilst Mitigating Risks & Navigate A Volatile Geopolitical Landscape To Drive
Robust, Resilient, Transparent & Innovative
Risk & Compliance Strategies Across Pharmaceuticals & Life Sciences
4th Annual, Industry-Led Conference & Networking Exhibition | One America Square, London | 1st October 2026
08.30 Registration & Informal Networking
Opening Remarks
09.00 GIC Welcome & Morning Chair’s Opening Remarks
Kiki Merakli, VP, Chief Compliance Officer, Sobi
ABPI CASE STUDY:
09.10 TOPIC OF CASE STUDY TO BE CONFIRMED
Andy Collier, Senior Policy Manager, ABPI
Regulatory Updates & Trends
PANEL Q&A
09.30 Unpack Critical Emerging Regulatory Shifts, Stay Ahead Of The Curve & Unpack What’s Next For Compliance Professionals in 2026 & Beyond
- Drive the shift towards agile and risk-based regulatory frameworks to proactively tackle regulatory compliance developments and challenges
- Unpack the latest legislative and enforcement developments and translate regulatory change into clear and actionable priorities
- Analyse the potential impact of new and upcoming frameworks such as the EU AI Act and data protection policies to identify where scrutiny is intensifying and how professionals can proactively assess their controls and frameworks
- Look beyond immediate updates to assess long-term regulatory shifts to equip risk and compliance professionals with forward-looking strategies to remain agile and resilient in an increasingly complex global and regulatory landscape
Dr Corlia Van Der Walt, Director: R&D Partnerships & Legal Compliance, AstraZeneca
Alicia White, Director, PMCPA
Dhananjay Bhavsar, Quality Regulatory Compliance Inspection & Audits Expert, Sandoz
10.00 Bonus Session; Reserved For Exclusive Conference Partner
10.20 Morning Refreshment Break With Informal Networking
AI User Cases & Implementation
Opening Keynote
10.50 Achieve Effective AI Implementation & Master Regulatory Framework Development To Accelerate Organisation-Wide Adoption
- What are the current established uses of AI in compliance and what new trends are emerging? Deep-dive into the emerging best practices for AI adoption to enhance operations and efficiencies across the organisation
- Monitor the regulatory challenges around adopting new technologies and create coherent and comprehensive strategies for internal AI policies that enable effective implementation
- Keeping the human in the loop: from updated training techniques to promoting digital literacy across the workforce, how can responsible AI behaviours best be encouraged and monitored to ensure awareness of patient safety, data protection and bias mitigation?
- What lessons can be learned from AI implementation within the pharmaceuticals industry? Unpack the insights and troubleshooting from AI adoption to reframe your approaches in the future
Enrique Grande Jarque, Head of Ethics & Compliance Iberia, Takeda
Data Privacy, Analysis & Integrity
NEW STRATEGIES
11.10 Strengthen Data Privacy Governance & Utilise Advanced Analytics To Mitigate Risk & Safeguard Patient Trust
- Leverage advanced analytics and data insights responsibility while maintaining strict adherence to GDPR and emerging global data privacy regulations
- Identify, assess and mitigate data risks through techniques such as validation controls, robust oversight and monitoring mechanisms
- Build resilient and comprehensive systems that protect data integrity, reinforce regulatory confidence and sustain patient trust in an increasingly data-driven pharmaceutical landscape
- Strengthen data governance frameworks to ensure secure and compliant collection, storage and analysis of sensitive data
Amanda King, Head of Data Privacy, Digital & AI UK, Ireland & Nordics, Novartis
Compliance Cultures
PANEL Q&A
11.30 Embed Integrity At Every Level & Transform Compliance From Obligation To Organisational Mindset
- What is a culture of compliance? Define and measure what “good” looks like through tangible indicators of a healthy risk and compliance culture and embed integrity by design
- Empower leadership to set the tone from the top and model ethical decision-making, reinforce accountability and foster a productive and proactive approach to compliance across every level of the organisation
- Rethink training to drive real behavioural change and develop effective metrics to track data, feedback and measurable outcomes for these new strategies
- Leverage behavioural science, digital tools, and AI to drive measurable change in training effectiveness
- Foster trust in measures such as speak up culture, ensure consistent investigation standards and continuously monitor culture beyond tick-box assessments and exercises
Vinod Koshy, Director, Global Healthcare Compliance, Advanz Pharma
Jelena Danilovic, Head of Compliance, Hemofarm A.D.
Nicola Galtieri, Head of Global Ethics & Compliance, Kedrion Biopharma
Antonios Roussos, Head of Global E&C Data Privacy & Group DPO, Astellas
Birgitta Strinnholm, Nordic Market Ethics Lead, AstraZeneca
Zoe Buch, Third Party Risk Management & Enterprise Compliance, EMEA, Johnson & Johnson
Third-Party Risk Management
DOUBLE PERSPECTIVE
Elevate Third-Party Risk Management Frameworks To Ensure Rigorous Compliance, Strengthen Oversight & Build Resilient Supply Chains
- Move beyond reactive compliance monitoring by utilising assessment data, internal audits and continuous oversight to enact measurable improvements and optimise third-party performance
- Develop proactive due diligence approaches to identify vulnerabilities early and mitigate regulatory and operational threats
- Anticipate the next evolution of third-party risk management by addressing emerging geopolitical, regulatory and operational risks while building partnerships founded on trust and resilience
12.05 Perspective One
Lucy Sales, Senior Director – Risk & Compliance, AstraZeneca
12.25 Perspective Two
Jesus Cativiela Rodriguez, Privacy & Legal Director, Almirall
12.45 Lunch & Informal Networking For Speakers, Delegates & Partners
Break out session in lunch: Cross Boarder Process
Alexis Pagé, Business Ethics Director, Ipsen
OPENING REMARKS
13.45 Afternoon Chair’s Opening Remarks
Karen Allman, Head, Global Compliance, ViiV Healthcare
13.55 Bonus Session; Reserved For Exclusive Conference Partner
Geopolitics & International Risk
PANEL Q&A
14.15 Embed Proactive & Strategic Approaches To Navigate Geopolitical Uncertainty Amidst A Volatile Global Landscape
- Leverage your logistics: examine how to systematically monitor geopolitical disruption and anticipate the potential impacts within your organisation and functions
- Craft agile frameworks & safeguard operational continuity while upholding ethical standards and compliance obligations in areas facing instability or uncertainty
- Move beyond awareness to action – assess the implications of political and regulatory developments across the supply chain, market access and third-party partnerships
- Promote proactivity over reactivity by designing agile governance structures and strategies that enable confident decision-making in uncertain times
- Mitigate the risk of data loss and digital disruption across operations and supply chains in conflict scenarios
Tetiana Isaieva, Head of Compliance EEMEAIS, Roche
Marion Pillwein, Senior Director Quality Assurance, Octapharma
Liam O’Shaughnessy, Compliance Director – External Affairs & Comms & Global Commercial Strategy, ViiV
Georgii Sibirtsev, Senior Legal & Compliance Associate, Bayer
Michelle Koleosho, Legal Director, MSD
14.45 Afternoon Refreshment Break With Informal Networking
Monitoring & Auditing
15.15 Utilise Technologies & Monitoring Techniques To Drive Continuous Assurance & Transform Oversight Into Strategic Advantage
- How can AI-enabled risk sensing compress assessment cycles and what governance is required to trust and act on those signals?
- Which decision-grade metrics should boards require to oversee data integrity, model performance, and compliance in near real time?
- How do organisations redesign assurance to run continuous checks without blurring accountability across the lines of defence?
- How do we combine real-time analytics and risk-based sampling with escalation protocols, so issues are detected early and acted on safely?
- What must the board approve when assurance becomes intelligent?
Stefan Nickels, Global Director Internal Audit, Daiichi Sankyo
HCP Interaction & Engagement
PANEL Q&A
15.35 Define Powerful Strategies For Embedding Integrity, Transparent & Control Across All HCP Touchpoints
- Redefine HCP engagement models without compromising integrity: maintain a clear and defensible distinction between scientific exchange and commercial influence across every channel
- Prevent the blurring of promotional vs non-promotional lines and uphold compliance standards across diverse interaction platforms to cultivate compliant relationships with HCPs
- Anticipate regulatory, enforcement and media scrutiny by utilising data-driven monitoring and proactive risk identification to protect both reputation and patient trust
Sylvia Oba, Global Markets Ethics, Compliance & Privacy Director, Servier
Aymeric Lannoy , Head of Compliance & Ethics Benelux, Switzerland & Austria – Associate Director, Bristol Myers Squibb
Pia Weckendorf, Head of Internal Audit , Grünenthal Group
Louise Strom, Head of Legal & Compliance (UK, Ireland & Nordics), Galderma
16.05 Afternoon Chair’s Closing Remarks & Official Close Of Conference
16:15 Official Close Of Conference
